Bone Grafts and Substitutes Market expected to reach USD 3.48 Billion Globally in 2023

The Global bone grafts and substitutes market was valued at USD 2.35 billion in 2014 and is anticipated to expand at a CAGR of 4.5% from 2015 to 2023 to reach USD 3.48 billion in 2023.

 

Bones have the natural ability to heal, but if the defects surpass a critical size, then surgical intervention is often required to regenerate the bone. Hence, presently, various bone grafts and substitutes are available to regenerate the bone. According to the American Academy of Orthopaedic Surgeons, the ideal bone graft substitute (BGS) is biocompatible, easy to use, osteoinductive, osteoconductive, structurally similar to bone, and cost effective. Factors such as rapid technological changes from autografts to allografts and penetration of synthetic and tissue engineered bone grafts in the market are propelling the growth of the bone grafts and substitutes market. Moreover, increasing demand from customers and rising industry standards are spurring the growth of the global bone grafts and substitutes market. Additionally, according to the International Osteoporosis Foundation, worldwide incidence of fracture is anticipated to increase by 240% in women and 310% in men by 2050. Thus, these factors are expected to drive the global bone grafts and substitutes market during the forecast period from 2015 to 2023.

 

The global bone grafts and substitutes (BGS) market has been categorized into allografts and bone graft substitutes. The allografts segment includes demineralized bone matrix (DBM) and other allografts (freeze-dried bone and fresh frozen bone). The bone graft substitutes segment has been further classified into synthetic bone grafts, bone morphogenetic protein (BMP), and others. 

 

Allograft is a tissue graft which is received from a donor of the same species; it is not genetically identical as an autograft. Allografts possess both osteoinductive and osteoconductive properties, and hence serve as a substitute for autografts. Ready availability of allografts in various shapes and sizes that can be processed in various forms such as chips and others as per requirement is likely to be one of the major factors fueling the growth of the allografts segment during the forecast period from 2015 to 2023. In the U.S., approximately one third of bone graft procedures use allografts, however risk of infection transmission is associated with its usage. Therefore, in order to minimize the risk of diseases transmission, allograft tissue is treated with several techniques such as tissue freezing, freeze drying, and sterilization. Thus, these factors collectively propel the growth of the allografts segment. The allografts segment is anticipated to reach USD 1,148.0 million in 2023 at a CAGR of 3.9% during the forecast period from 2015 to 2023. 

 

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6200

 

Bone graft substitutes is the fastest growing segment of the global bone grafts and substitutes market. The bone graft substitutes segment comprises synthetic bone grafts, bone morphogenetic proteins (BMP), and others. Factors such as increasing procedural volume of spinal fusion and joint reconstruction due to rising geriatric population and launch of innovative products are the major factors supporting the growth of this segment. Bone morphogenetic proteins (BMP) accounted for the largest share of around 34% of the bone graft substitutes segment in 2014. BMPs are a group of growth factors that play a significant role in bone induction, regulation, and repair. Technological advances in biochemical techniques and research and development has led to the introduction of two FDA-approved commercial products named rhBMP-2 (INFUSE by Medtronic plc) and rhBMP-7 (OP-1 by Stryker). Growth of the BMP segment is primarily driven by advantages over allograft tissues, which present a potential risk of disease transmission, morbidity, and availability issues, and high cost of commercially available BMP products.